Sublingual allergoid immunotherapy: A new 4-day induction phase in patients allergic to house dust mites

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 2, 2010, Pages 553-560

  D'Anneo, R W ^a   Bruno, Marco E ^b   Falagiani, P ^b  

^a Papardo Hospital   (Italy)

^b Lofarma SpA   (Italy)

Author keywords

Asthma; House dust mites; Monomeric carbamylated allergoid; Rhinitis; Sublingual immunotherapy

Indexed keywords

BECLOMETASONE; CETIRIZINE; DESLORATADINE; FLUTICASONE PROPIONATE; HISTAMINE; HOUSE DUST ALLERGEN; HOUSE DUST MITE ALLERGOID; LAIS; LORATADINE; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES; DRUG SAFETY; FEMALE; HOUSE DUST; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; MALE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; MOUTH EDEMA; NASAL PRURITUS; OPEN STUDY; PRICK TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOCONJUNCTIVITIS; SENSITIZATION; SKIN TEST; TABLET; THERAPY EFFECT; TREATMENT DURATION; VISUAL ANALOG SCALE; WELLBEING;

EID: 77955383100     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300217     Document Type: Article

References (15)

1. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351:629-32.
2. Lombardi C, Gargioni S, Melchiorre A, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy 2001; 56:989-92. (Pubitemid 32835605)
3. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999; 54:1110-3. (Pubitemid 29482012)
4. Rossi RE, Monasterolo G. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005; 18:277-85. (Pubitemid 40825890)
5. Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheinmann P, Ruffin P et al. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 2002; 129:248-53. (Pubitemid 35365366)
6. Passalacqua G, Lombardi C, Guerra L, Compalati E, Fumagalli F, Canonica GW. Sublingual immunotherapy: no more doubts. Eur Ann Allergy Clin Immunol 2005; 37:314-20.
7. Giordano T, Quarta C, Bruno ME, Falagiani P, Riva G. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase. Eur Ann Allergy Clin Immunol 2006; 9:310-2. (Pubitemid 46032847)
8. Bousquet PJ, Combescure C, Klossek JM, Daurès JP, Bousquet J. Changes in visual analogue scale in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol 2009; 123:1349-54.
9. Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P. Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy 1996; 51:8-15. (Pubitemid 26104694)
10. Pfaar O, Klimek L: for the Study Group. Efficacy and safety of specific immunotherapy with a high dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma. Immunol 2008; 100:256-63.
11. Gammeri E, Arena A, D'Anneo R, La Grutta S. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol 2005; 33:142-4. (Pubitemid 40896350)
12. Durham SR, Yang WH, Pedersen MR, Johansen N, Eng Msc-C, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-9.
13. Cosmi L, Santarlasci V, Angeli R, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-γ- and interleukin-10- production. Clin Exp Allergy 2006; 36:261-72.
14. Calderon M, Essendrop M. Specific Immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated. J Invest Clin Immunol 2006; 16:338-44. (Pubitemid 44953951)
15. Di Gioacchino M, Perrone A, Petrarca C, et al. Early cytokine modulation after the rapid induction phase of sublingual immunotherapy with mite monomeric allergoids. Int J Immunopathol Pharmacol 2008; 21:969-76